ERBB2 and cancer: In the passage of the Her2+ cell line BT-474 (Figure 6e) we did not detect significant effects on transmigration, neither after differentiation of cancer and endothelial cells with E2 (0.91 ± 0.13; p = 0.73) (2), nor following the treatment of cancer and endothelial cells with DPN (1.06 ± 0.10; p = 0.37) (3).